The role of serum asprosin levels in predicting the severity of coronary artery disease in patients with diabetes mellitus.
Asprosin
Coronary artery disease
Diabetes mellitus
SYNTAX score
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
received:
08
10
2023
accepted:
22
01
2024
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
aheadofprint
Résumé
Asprosin is an emerging biomarker that plays a role in metabolic diseases. This study investigates asprosin as a predictive marker for coronary artery disease (CAD) severity in diabetic patients. Diabetic patients (n = 181) and healthy controls (n = 60) were analyzed. CAD severity was assessed using SYNTAX score. Diabetic patients were divided into 3 groups. Group 1 = patients without CAD, group 2 = patients with low SYNTAX score, and group 3 = patients with moderate-high SYNTAX score. Asprosin levels were measured for all participants using an enzyme-linked immunosorbent assay (ELISA). Asprosin levels were significantly higher in patient group compared to control group (p < 0.001). Asprosin levels were significantly higher in group 3 compared to group 1 and group 2 (p = 0.002). In logistic regression analysis, asprosin levels independently predicted patients with moderate-high SYNTAX scores. According to this analysis, 1 ng/mL increase in asprosin level was found to increase the risk of having moderate-high SYNTAX score by 14.1%. When the threshold value of asprosin level was set as 22.17 ng/mL, it predicted patients with moderate-high SYNTAX score with 63.6% sensitivity and 62.6% specificity. In multivariate regression analysis, SYNTAX score independently correlated with asprosin level. This is the first study in the literature to demonstrate a positive correlation between asprosin levels and SYNTAX scores in diabetic patients with CAD. More comprehensive studies with larger groups are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Asprosin is an emerging biomarker that plays a role in metabolic diseases. This study investigates asprosin as a predictive marker for coronary artery disease (CAD) severity in diabetic patients.
METHODS
METHODS
Diabetic patients (n = 181) and healthy controls (n = 60) were analyzed. CAD severity was assessed using SYNTAX score. Diabetic patients were divided into 3 groups. Group 1 = patients without CAD, group 2 = patients with low SYNTAX score, and group 3 = patients with moderate-high SYNTAX score. Asprosin levels were measured for all participants using an enzyme-linked immunosorbent assay (ELISA).
RESULTS
RESULTS
Asprosin levels were significantly higher in patient group compared to control group (p < 0.001). Asprosin levels were significantly higher in group 3 compared to group 1 and group 2 (p = 0.002). In logistic regression analysis, asprosin levels independently predicted patients with moderate-high SYNTAX scores. According to this analysis, 1 ng/mL increase in asprosin level was found to increase the risk of having moderate-high SYNTAX score by 14.1%. When the threshold value of asprosin level was set as 22.17 ng/mL, it predicted patients with moderate-high SYNTAX score with 63.6% sensitivity and 62.6% specificity. In multivariate regression analysis, SYNTAX score independently correlated with asprosin level.
CONCLUSION
CONCLUSIONS
This is the first study in the literature to demonstrate a positive correlation between asprosin levels and SYNTAX scores in diabetic patients with CAD. More comprehensive studies with larger groups are needed.
Identifiants
pubmed: 38300461
doi: 10.1007/s11845-024-03616-6
pii: 10.1007/s11845-024-03616-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
Committee ADAPP 2 (2021) Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care 45(Supplement_1):S17–S38
Romere C, Duerrschmid C, Bournat J et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165(3):566–579. https://doi.org/10.1016/j.cell.2016.02.063
doi: 10.1016/j.cell.2016.02.063
pubmed: 27087445
pmcid: 4852710
Yuan M, Li W, Zhu Y et al (2020) Asprosin: a novel player in metabolic diseases. Front Endocrinol (Lausanne). 11:64. https://doi.org/10.3389/fendo.2020.00064
doi: 10.3389/fendo.2020.00064
pubmed: 32153505
pmcid: 7045041
Farrag M, Eldjoudi DA, González-Rodríguez M et al (2023) Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects. Front Endocrinol (Lausanne). 13:1101091. https://doi.org/10.3389/fendo.2022.1101091
doi: 10.3389/fendo.2022.1101091
pubmed: 36686442
pmcid: 9849689
Grundy SM, Benjamin IJ, Burke GL et al (2000) Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100(10):1134–1146. https://doi.org/10.1161/01.cir.100.10.1134
doi: 10.1161/01.cir.100.10.1134
Moradi N, Fouani FZ, Vatannejad A et al (2021) Serum levels of asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study. Lipids Health Dis 20(1):88. https://doi.org/10.1186/s12944-021-01514-9
doi: 10.1186/s12944-021-01514-9
pubmed: 34419063
pmcid: 8380384
Güven C, Kafadar H (2022) Evaluation of plasma asprosin concentration in patients with coronary artery disease. Braz J Cardiovasc Surg 37(4):493–500. https://doi.org/10.21470/1678-9741-2021-0003
doi: 10.21470/1678-9741-2021-0003
pubmed: 35072406
pmcid: 9423794
Sianos G, Morel M-A, Kappetein AP et al (2005) The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227
pubmed: 19758907
Serruys PW, Morice M-C, Kappetein AP et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972. https://doi.org/10.1056/NEJMoa0804626
doi: 10.1056/NEJMoa0804626
pubmed: 19228612
Acara AÇ, Bolatkale M, Kızıloğlu İ et al (2018) A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med 36(8):1504–1505. https://doi.org/10.1016/j.ajem.2017.12.032
doi: 10.1016/j.ajem.2017.12.032
pubmed: 29274804
Zhang Z, Tan Y, Zhu L et al (2019) Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci 231:116554. https://doi.org/10.1016/j.lfs.2019.116554
doi: 10.1016/j.lfs.2019.116554
pubmed: 31194992
Wen M-S, Wang C-Y, Yeh J-K et al (2020) The role of asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord 20(1):402. https://doi.org/10.1186/s12872-020-01680-1
doi: 10.1186/s12872-020-01680-1
pubmed: 32894050
pmcid: 7487662
Feng J, Yang Y, Yang Y et al (2018) GW29-e0080 the protective role of asprosin against diabetes in cardiomyocytes. J Am Coll Cardiol 72(16S):C2. https://doi.org/10.1016/j.jacc.2018.08.012
doi: 10.1016/j.jacc.2018.08.012
Chen S, Wang X, Qiu CM et al (2019) Study of the role and mechanism of asprosin/spartin pathway in cardiac microvascular endothelial injury induced by diabete mellitus. Sichuan da xue xue bao Yi xue ban= J Sichuan Univ (Med Sci Ed) 50(6):827–834
Kundu A, Sardar P, O’Day K et al (2018) SYNTAX score and outcomes of coronary revascularization in diabetic patients. Curr Cardiol Rep 20(5):28. https://doi.org/10.1007/s11886-018-0971-1
doi: 10.1007/s11886-018-0971-1
pubmed: 29572680